As US and European regulators look to boost interest and participation in the parallel scientific advice program for complex generics, a fee that sponsors don't want to pay could be hindering participation just as some may not be aware of the program at all.
The program allows sponsors to meet with US Food and Drug Administration and European Medicines Agency officials to gain alignment...